BR112023002646A2 - Compostos de heteroarila substituída úteis como inibidores de tlr9 - Google Patents
Compostos de heteroarila substituída úteis como inibidores de tlr9Info
- Publication number
- BR112023002646A2 BR112023002646A2 BR112023002646A BR112023002646A BR112023002646A2 BR 112023002646 A2 BR112023002646 A2 BR 112023002646A2 BR 112023002646 A BR112023002646 A BR 112023002646A BR 112023002646 A BR112023002646 A BR 112023002646A BR 112023002646 A2 BR112023002646 A2 BR 112023002646A2
- Authority
- BR
- Brazil
- Prior art keywords
- substituted heteroaryl
- compounds
- compounds useful
- heteroaryl compounds
- tlr9 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067465P | 2020-08-19 | 2020-08-19 | |
| PCT/US2021/046434 WO2022040267A1 (en) | 2020-08-19 | 2021-08-18 | 1h-pyrrolo[3,2-c]pyridine and 1h-pyrrolo[2,3-c]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002646A2 true BR112023002646A2 (pt) | 2023-04-04 |
Family
ID=77711459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002646A BR112023002646A2 (pt) | 2020-08-19 | 2021-08-18 | Compostos de heteroarila substituída úteis como inibidores de tlr9 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12590091B2 (https=) |
| EP (1) | EP4200298B1 (https=) |
| JP (1) | JP2023538608A (https=) |
| KR (1) | KR20230053646A (https=) |
| CN (1) | CN115867549A (https=) |
| AR (1) | AR123285A1 (https=) |
| AU (1) | AU2021328577A1 (https=) |
| BR (1) | BR112023002646A2 (https=) |
| CA (1) | CA3189826A1 (https=) |
| ES (1) | ES3034264T3 (https=) |
| IL (1) | IL300643A (https=) |
| MX (1) | MX2023001929A (https=) |
| TW (1) | TW202214233A (https=) |
| WO (1) | WO2022040267A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| KR20240148414A (ko) * | 2022-02-18 | 2024-10-11 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr9의 억제제로서 유용한 치환된 이미다조피리디닐 화합물 |
| WO2024102886A1 (en) * | 2022-11-10 | 2024-05-16 | Bristol-Myers Squibb Company | Substituted benzimidazole compounds useful as inhibitors of tlr9 |
| CN120152957A (zh) * | 2022-11-10 | 2025-06-13 | 百时美施贵宝公司 | 用作tlr9抑制剂的经取代的喹诺酮 |
| WO2024163380A1 (en) * | 2023-01-31 | 2024-08-08 | Bristol-Myers Squibb Company | Substituted benzimidazole compounds useful as inhibitors of tlr9 |
| IL324670A (en) | 2023-06-30 | 2026-01-01 | Bristol Myers Squibb Co | KRAS inhibitors |
| WO2026039512A1 (en) | 2024-08-14 | 2026-02-19 | Bristol-Myers Squibb Company | Kras inhibitors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007115306A2 (en) | 2006-04-04 | 2007-10-11 | Myriad Genetics, Inc. | Compounds for diseases and disorders |
| US20060235037A1 (en) | 2005-04-15 | 2006-10-19 | Purandare Ashok V | Heterocyclic inhibitors of protein arginine methyl transferases |
| GB0602178D0 (en) | 2006-02-03 | 2006-03-15 | Merck Sharp & Dohme | Therapeutic treatment |
| CA2738929A1 (en) | 2008-10-17 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as mmp-13 inhibitors |
| US20130158049A1 (en) | 2011-12-20 | 2013-06-20 | Hoffmann-La Roche Inc. | 7-azaindole inhibitors of crac |
| US20130158066A1 (en) | 2011-12-20 | 2013-06-20 | Hoffmann-La Roche Inc. | 4-azaindole inhibitors of crac |
| WO2013156431A1 (en) | 2012-04-17 | 2013-10-24 | Syngenta Participations Ag | Pesticidally active pyridyl- and pyrimidyl- substituted thiazole and thiadiazole derivatives |
| EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| EP3080124A1 (en) * | 2013-12-13 | 2016-10-19 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
| AR107032A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| MX391344B (es) | 2016-07-30 | 2025-03-21 | Bristol Myers Squibb Co | Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9). |
| KR102519535B1 (ko) | 2016-09-09 | 2023-04-06 | 브리스톨-마이어스 스큅 컴퍼니 | 피리딜 치환된 인돌 화합물 |
| US11370794B2 (en) * | 2016-11-11 | 2022-06-28 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| CN110891949B (zh) | 2017-07-05 | 2023-05-23 | 先正达参股股份有限公司 | 具有含硫取代基的杀有害生物活性杂环衍生物 |
| CN110997656B (zh) | 2017-08-04 | 2023-04-14 | 百时美施贵宝公司 | 用作tlr7/8/9抑制剂的取代的吲哚化合物 |
| ES2921020T3 (es) | 2017-08-04 | 2022-08-16 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo |
| CN111448190B (zh) | 2017-11-14 | 2023-09-26 | 百时美施贵宝公司 | 取代的吲哚化合物 |
| BR112020011668A2 (pt) | 2017-12-15 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de éter de indol substituído |
| FI3728252T3 (fi) | 2017-12-18 | 2023-10-18 | Bristol Myers Squibb Co | 4-atsaindoliyhdisteitä |
| JP7313354B2 (ja) | 2017-12-19 | 2023-07-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物 |
| WO2019126082A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | 6-azaindole compounds |
| BR112020012084A2 (pt) | 2017-12-19 | 2020-11-24 | Bristol-Myers Squibb Company | compostos de indol substituído úteis como inibidores de tlr |
| CA3085942A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
| US11299501B2 (en) | 2017-12-20 | 2022-04-12 | Bristol-Myers Squibb Company | Diazaindole compounds |
| BR112020011984A2 (pt) | 2017-12-20 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de amino indol úteis como inibidores de tlr |
| MX2021001565A (es) | 2018-08-08 | 2021-04-19 | Bristol Myers Squibb Co | Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad). |
-
2021
- 2021-08-18 AU AU2021328577A patent/AU2021328577A1/en not_active Abandoned
- 2021-08-18 KR KR1020237009022A patent/KR20230053646A/ko active Pending
- 2021-08-18 BR BR112023002646A patent/BR112023002646A2/pt not_active Application Discontinuation
- 2021-08-18 CN CN202180050340.3A patent/CN115867549A/zh active Pending
- 2021-08-18 MX MX2023001929A patent/MX2023001929A/es unknown
- 2021-08-18 TW TW110130428A patent/TW202214233A/zh unknown
- 2021-08-18 WO PCT/US2021/046434 patent/WO2022040267A1/en not_active Ceased
- 2021-08-18 AR ARP210102329A patent/AR123285A1/es not_active Application Discontinuation
- 2021-08-18 US US18/042,069 patent/US12590091B2/en active Active
- 2021-08-18 ES ES21769261T patent/ES3034264T3/es active Active
- 2021-08-18 IL IL300643A patent/IL300643A/en unknown
- 2021-08-18 EP EP21769261.5A patent/EP4200298B1/en active Active
- 2021-08-18 JP JP2023512162A patent/JP2023538608A/ja active Pending
- 2021-08-18 CA CA3189826A patent/CA3189826A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230312565A1 (en) | 2023-10-05 |
| AU2021328577A1 (en) | 2023-03-23 |
| JP2023538608A (ja) | 2023-09-08 |
| KR20230053646A (ko) | 2023-04-21 |
| US12590091B2 (en) | 2026-03-31 |
| AR123285A1 (es) | 2022-11-16 |
| IL300643A (en) | 2023-04-01 |
| ES3034264T3 (en) | 2025-08-14 |
| TW202214233A (zh) | 2022-04-16 |
| MX2023001929A (es) | 2023-03-09 |
| EP4200298B1 (en) | 2025-05-21 |
| CN115867549A (zh) | 2023-03-28 |
| WO2022040267A1 (en) | 2022-02-24 |
| CA3189826A1 (en) | 2022-02-24 |
| EP4200298A1 (en) | 2023-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023002646A2 (pt) | Compostos de heteroarila substituída úteis como inibidores de tlr9 | |
| BR112023002662A2 (pt) | Compostos de heteroarila substituída úteis como inibidores de tlr9 | |
| BR112022009514A2 (pt) | Compostos úteis como inibidores de proteína helios | |
| MX2024001824A (es) | Compuestos heterociclicos y metodos de uso. | |
| BR112022007783A2 (pt) | Composto, composição farmacêutica, e, métodos para inibir proteína g12c de kras e para tratar câncer | |
| JOP20230318A1 (ar) | مشتقات تترا هيدرو – إيميدازوبيريدين كمعدِّلات مناعية pd-l1 | |
| SA522431915B1 (ar) | Prmt5 مثبطات mta تعاونية مع | |
| BR112021024810A2 (pt) | Composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer e método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas | |
| CU20210065A7 (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2 | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| BR112022020841A2 (pt) | Inibidores de kras tricíclicos fundidos | |
| BR112022002698A2 (pt) | Compostos de imidazolil pirimidinilamina como inibidores de cdk2 | |
| EP4506035A3 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
| BR112021021718A2 (pt) | Moduladores de thr-ss e métodos de uso dos mesmos | |
| BR112023021111A2 (pt) | Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2 | |
| BR112022012222A2 (pt) | Derivados de piperazina substituídos úteis como ativadores de células t | |
| BR112021023824A8 (pt) | Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica | |
| BR112021017049A2 (pt) | Derivados de tiazol como inibidores de secreção de proteínas | |
| BR112017022349A2 (pt) | ?composto, composição, método, e, método para inibir uma proteína irak? | |
| BR112022022535A2 (pt) | Composto, composição farmacêutica, método de tratamento de câncer, método de inibição seletiva, método de redução de um nível de ros1 ou alk | |
| BR112015022462A8 (pt) | inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| BR112023003580A2 (pt) | Compostos heterocíclicos | |
| ZA202304541B (en) | Cdk inhibitors and their use as pharmaceuticals | |
| MX2023007265A (es) | Inhibidores de cdk y su uso como productos farmacéuticos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |